CIDARA THERAPEUTICS INC (CDTX)

US1717572069 - Common Stock

11.21  -0.79 (-6.58%)

News Image
3 days ago - TheNewswire.com

CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from allegations that Cidara Therapeutics may have issued materially misleading business information to the investing public.

News Image
3 days ago - NewMediaWire

CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image
4 days ago - BusinessInsider

CDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cidara Therapeutics (NASDAQ:CDTX) just reported results for the first quarter o...

News Image
4 days ago - InvestorPlace

CDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024

CDTX stock results show that Cidara Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image
4 days ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary...

News Image
4 days ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...

News Image
6 days ago - TheNewswire.com

CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from allegations that Cidara Therapeutics may have issued materially misleading business information to the investing public.

News Image
6 days ago - NewMediaWire

CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image
9 days ago - THE ROSEN LAW FIRM, P. A.

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

News Image
23 days ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary...

News Image
24 days ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are a great way to start Thursday as we check out all of the hottest news moving shares this morning!

News Image
25 days ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and...

News Image
a month ago - InvestorPlace

CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023

CDTX stock results show that Cidara Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

News Image
a month ago - BusinessInsider

CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cidara Therapeutics (NASDAQ:CDTX) just reported results for the fourth quarter ...

News Image
a month ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary...

News Image
a month ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary...

News Image
a month ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Reverse Stock Split

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary...

News Image
a month ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC...

News Image
3 months ago - Seeking Alpha

Cidara receives $11M milestone payment from partner Mundipharma (NASDAQ:CDTX)

Cidara (CDTX) said it has received an $11.14M milestone payment from partner Mundipharma related to the European approval of its antifungal drug Rezzayo. Read more here.

News Image
4 months ago - Seeking Alpha

Cidara rallies 13% after hours on UK approval for Rezzayo (NASDAQ:CDTX)

Shares of Cidara Therapeutics (CDTX) rallied 13% in post-market trading Monday after the company said it had received UK regulatory approval for its drug Rezzay

News Image
4 months ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

The UK MHRA approval follows approvals by the U.S. FDA and the European CommissionCidara is entitled to receive a milestone payment of approximately $2.8...

News Image
5 months ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

Approval based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive...

News Image
6 months ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Top-line data expected in Q2 2024 SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing...

News Image
6 months ago - Seeking Alpha

Cidara, Melinta announce publication of Rezzayo data in medical journal (NASDAQ:CDTX)

Shares of Cidara Therapeutics (CDTX) rose 7% after it announced publication of pooled data for Rezzayo in The Lancet Infectious Diseases. Read more here.

News Image
6 months ago - Cidara Therapeutics, Inc.

Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time...

News Image
7 months ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...

News Image
7 months ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapies...

News Image
7 months ago - Cidara Therapeutics, Inc.

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and...

News Image
7 months ago - Cidara Therapeutics, Inc.

Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...